Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features
Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features
复制标题
DOI：
10.1038/sj.bjc.6601198
复制
发表时间：
2003-08-18
影响因子：
8.8
通讯作者：
Robertson, JFR
中科院分区：
文献类型：
--
作者：
James, JJ;Evans, AJ;Robertson, JFR
这项研究的目的是确定可能与转移性乳腺癌患者骨转移发展相关的因素，并看看这些因素是否对随后的生存有影响。1997年7月至2001年12月期间，共有492名转移性乳腺癌患者到诺丁汉市医院就诊。其中，267例患者在出现转移性疾病时发生骨转移，该组中91例患者仅发生骨转移。前瞻性记录转移性疾病首次出现的部位，以及原发肿瘤的组织学特征（肿瘤类型、组织学分级、淋巴结分期、肿瘤大小和雌激素受体（ER）状态）。记录骨转移的放射学特征、无转移间隔和出现转移时的血清学肿瘤标志物水平。骨转移的发生与低级别肿瘤（P = 0.019）、er阳性肿瘤（P < 0.0001）和原发肿瘤的淋巴结分期（P = 0.047）有显著相关性。一项多变量分析发现，无转移期、骨以外转移性疾病的其他部位、内质网状态和血清学肿瘤标志物水平都独立地影响骨转移患者的生存。
The aim of this study was to identify factors that may be associated with the development of bone metastases in patients with metastatic breast carcinoma and to see if any of these factors had a bearing on subsequent survival. In total, 492 patients presented to the Nottingham City Hospital with metastatic breast carcinoma between July 1997 and December 2001. Of these, 267 patients had bone metastases at presentation with metastatic disease, 91 patients in this group had bone as their only site of metastatic disease. Sites of first presentation of metastatic disease were prospectively recorded, as were histological features of the primary tumour (tumour type, histological grade, lymph node stage, tumour size and oestrogen receptor (ER) status). The radiological features of the bone metastases, the metastasis-free interval and serological tumour marker levels at presentation with metastases were all recorded. There was a significant association between the development of bone metastases and lower grade tumours (P = 0.019), ER-positive tumours (P < 0.0001) and the lymph node stage of the primary tumour (P = 0.047). A multivariate analysis found that metastasis-free interval, additional sites of metastatic disease other than bone, ER status and serological tumour marker levels all independently contributed to survival from time of presentation with bone metastases.